This writer noticed that UK stock investors have been buying an obscure share that fell 26% yesterday but is still up nearly ...

The business of GLP-1s, it's mass adoption, compounded GLP-1s, compounding pharmacies, venture capital, and economic impact ...

Super Micro stock slumps with the server maker having until Tuesday to file delayed financial accounts or risk being delisted ...

We recently published a list of Jim Cramer on 10 Stocks With The Biggest Declines Last Week. In this article, we are going to ...

The tech-heavy Nasdaq Composite finished the volatile trading day down around 1.3%, dragged down by shares of Magnificent ...

People who have depended on off-brand versions of Wegovy and Ozempic will likely have to pay more now that a nationwide ...

You've probably seen the ads for GLP-1 drugs. It's a hormone that helps people lose weight, but the results are not ...

Hims & Hers (HIMS) made a killing last year selling an off-brand version of Ozempic, but with the drug’s shortage now over, ...

Hims & Hers stock tumbled after the company confirmed it would stop selling some compounded weight-loss drugs.

The pharma giant will now offer 7.5mg and 10mg dosages of Zepbound, as well as lower rates for its 2.5mg and 5mg vials.

The report suggests compounders may be using illegally imported APIs made in unregistered overseas facilities.

Hims & Hers Health, Inc. showcases strong growth with diverse revenue streams. Discover why its stock dip offers a unique opportunity. Learn more on HIMS stock here.